Literature DB >> 28573168

Analysis of in vivo Interaction between RNA Binding Proteins and Their RNA Targets by UV Cross-linking and Immunoprecipitation (CLIP) Method.

Pamela Bielli1,2, Claudio Sette1,2.   

Abstract

RNA metabolism is tightly controlled across different tissues and developmental stages, and its dysregulation is one of the molecular hallmarks of cancer. Through direct binding to specific sequence element(s), RNA binding proteins (RBPs) play a pivotal role in co- and post-transcriptional RNA regulatory events. We have recently demonstrated that, in pancreatic cancer cells, acquisition of a drug resistant (DR)-phenotype relied on upregulation of the polypyrimidine tract binding protein (PTBP1), which in turn is recruited to the pyruvate kinase pre-mRNA and favors splicing of the oncogenic PKM2 variant. Herein, we describe a step-by-step protocol of the ultraviolet (UV) light cross-linking and immunoprecipitation (CLIP) method to determine the direct binding of a RBP to specific regions of its target RNAs in adherent human cell lines.

Entities:  

Keywords:  CLIP; Protein-RNA interaction; Protein-RNA-immunoprecipitation; RNA processing

Year:  2017        PMID: 28573168      PMCID: PMC5448666          DOI: 10.21769/BioProtoc.2274

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  26 in total

Review 1.  Mechanisms of alternative pre-messenger RNA splicing.

Authors:  Douglas L Black
Journal:  Annu Rev Biochem       Date:  2003-02-27       Impact factor: 23.643

Review 2.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

3.  Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Authors:  Maria Paola Paronetto; Manuela Cappellari; Roberta Busà; Simona Pedrotti; Roberta Vitali; Clay Comstock; Terry Hyslop; Karen E Knudsen; Claudio Sette
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 4.  Context-dependent control of alternative splicing by RNA-binding proteins.

Authors:  Xiang-Dong Fu; Manuel Ares
Journal:  Nat Rev Genet       Date:  2014-08-12       Impact factor: 53.242

Review 5.  mRNA localization: gene expression in the spatial dimension.

Authors:  Kelsey C Martin; Anne Ephrussi
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

6.  Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.

Authors:  Cristina Valacca; Serena Bonomi; Emanuele Buratti; Simona Pedrotti; Francisco Ernesto Baralle; Claudio Sette; Claudia Ghigna; Giuseppe Biamonti
Journal:  J Cell Biol       Date:  2010-09-27       Impact factor: 10.539

7.  The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation.

Authors:  Olga Anczuków; Avi Z Rosenberg; Martin Akerman; Shipra Das; Lixing Zhan; Rotem Karni; Senthil K Muthuswamy; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2012-01-15       Impact factor: 15.369

Review 8.  Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation.

Authors:  Vittoria Pagliarini; Chiara Naro; Claudio Sette
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

Review 9.  Transcriptional termination in mammals: Stopping the RNA polymerase II juggernaut.

Authors:  Nick J Proudfoot
Journal:  Science       Date:  2016-06-10       Impact factor: 47.728

10.  Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.

Authors:  S Calabretta; P Bielli; I Passacantilli; E Pilozzi; V Fendrich; G Capurso; G Delle Fave; C Sette
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

View more
  7 in total

1.  c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer.

Authors:  Cinzia Caggiano; Marco Pieraccioli; Valentina Panzeri; Claudio Sette; Pamela Bielli
Journal:  Nucleic Acids Res       Date:  2019-07-09       Impact factor: 16.971

2.  Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circularization.

Authors:  Vittoria Pagliarini; Ariane Jolly; Pamela Bielli; Valentina Di Rosa; Pierre De la Grange; Claudio Sette
Journal:  Nucleic Acids Res       Date:  2020-01-24       Impact factor: 16.971

3.  SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing.

Authors:  Song Zhu; Weiping Chen; Jizhong Wang; Ling Qi; Huilin Pan; Zhengfu Feng; Dongbo Tian
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

4.  LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.

Authors:  Feifei Pu; Jianxiang Liu; Doudou Jing; Fengxia Chen; Xin Huang; Deyao Shi; Wei Wu; Hui Lin; Lei Zhao; Zhenhao Zhang; Xiao Lv; Baichuan Wang; Zhicai Zhang; Zengwu Shao
Journal:  Int J Oncol       Date:  2022-03-04       Impact factor: 5.650

5.  N6-Adenosine Methylation of Socs1 mRNA Is Required to Sustain the Negative Feedback Control of Macrophage Activation.

Authors:  Jie Du; Wang Liao; Weicheng Liu; Dilip K Deb; Lei He; Phillip J Hsu; Tivoli Nguyen; Linda Zhang; Marc Bissonnette; Chuan He; Yan Chun Li
Journal:  Dev Cell       Date:  2020-11-20       Impact factor: 12.270

6.  ZFP36 promotes VDR mRNA degradation to facilitate cell death in oral and colonic epithelial cells.

Authors:  Xiangyu Wang; Xuejun Ge; Wang Liao; Yong Cao; Ran Li; Fang Zhang; Bin Zhao; Jie Du
Journal:  Cell Commun Signal       Date:  2021-08-11       Impact factor: 5.712

7.  The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.

Authors:  Valentina Panzeri; Isabella Manni; Alessia Capone; Chiara Naro; Andrea Sacconi; Silvia Di Agostino; Luisa de Latouliere; Andrea Montori; Emanuela Pilozzi; Giulia Piaggio; Gabriele Capurso; Claudio Sette
Journal:  Mol Oncol       Date:  2020-11-24       Impact factor: 7.449

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.